OncoMatch/Clinical Trials/NCT07776821
An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
Is NCT07776821 recruiting? Yes, currently enrolling (Sep 2026). This Phase 4 trial studies Enlonstobart combined with chemotherapy for induction therapy followed by concurrent radiother for uterine cervical neoplasms.
Treatment: Enlonstobart combined with chemotherapy for induction therapy followed by concurrent radiother — The objective of this clinical trial is to investigate the efficacy and safety of Enlonstobart combined with concurrent chemoradiotherapy following induction chemotherapy for locally advanced cervical cancer. The primary questions it aims to address are: Can the Enlonstobart combination regimen improve the objective response rate and disease control rate in patients with locally advanced cervical cancer? What is the safety and tolerability profile of this combination regimen, and will any unexpected serious adverse events occur? Participants will: Receive induction therapy with Enlonstobart in combination with chemotherapy agents (e.g., paclitaxel plus platinum); Receive Enlonstobart in combination with concurrent chemoradiotherapy (external beam radiation therapy plus brachytherapy, with concurrent chemotherapy); Undergo regular tumor imaging evaluations (CT/MRI) and hematological safety assessments; Cooperate in completing efficacy assessments, adverse event documentation, and long-term follow-up.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV A (other)
locally advanced cervical cancer ... classified as FIGO stage III-IV A as of 2018
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.5 × 10⁹/L, hemoglobin ≥ 90 g/dL, platelets ≥ 100 × 10⁹/L
Kidney function
Serum creatinine ≤ 1.5×ULN; if > 1.5×ULN, creatinine clearance ≥ 60 mL/min (Cockcroft-Gault)
Liver function
ALT, AST, ALP ≤ 2.5×ULN; if liver metastases present, ≤ 5×ULN; total bilirubin ≤ 1.5×ULN (≤ 3×ULN for Gilbert's syndrome)
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%
Bone marrow function: ANC ≥ 1.5 × 10⁹/L, hemoglobin ≥ 90 g/dL, platelets ≥ 100 × 10⁹/L; Liver function: ALT, AST, ALP ≤ 2.5×ULN; if liver metastases present, ≤ 5×ULN; total bilirubin ≤ 1.5×ULN (≤ 3×ULN for Gilbert's syndrome); Renal function: Serum creatinine ≤ 1.5×ULN; if > 1.5×ULN, creatinine clearance ≥ 60 mL/min (Cockcroft-Gault); Cardiac: LVEF ≥ 50%; Coagulation: PT, APTT, INR ≤ 1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07776821 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage FIGO STAGE III or FIGO STAGE IV A is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages